Tirzepatide (Mounjaro/Zepbound) Side Effects: A Microdosing Perspective
Side effects on GLP-1 medications scale with peak plasma concentration. Microdosing — splitting your weekly dose into daily or every-other-day fractions — keeps plasma levels lower and steadier, dramatically reducing the day-2 nausea spike and fatigue waves that drive many people to quit. Many users who fail standard weekly protocols succeed on a microdose schedule. The strategies below work for both schedules, but microdosers often need lighter intervention.
Important Disclaimer
This article is for research purposes only. The information provided is based on available research data and should not be used for medical decision-making. Always consult with your healthcare provider about any concerns regarding medication side effects.
Overview of Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist used for the treatment of type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). While generally well-tolerated, it can cause both common and serious side effects. This article provides a comprehensive overview of these effects and their management.
Common Side Effects
Most Common Side Effects
- Nausea (15-25% of users)
- Vomiting (5-10% of users)
- Diarrhea (10-15% of users)
- Constipation (5-10% of users)
- Abdominal pain (5-10% of users)
- Decreased appetite (15-25% of users)
- Fatigue (5-10% of users)
- Dizziness (5-10% of users)